ATE384047T1 - Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren - Google Patents

Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren

Info

Publication number
ATE384047T1
ATE384047T1 AT01965225T AT01965225T ATE384047T1 AT E384047 T1 ATE384047 T1 AT E384047T1 AT 01965225 T AT01965225 T AT 01965225T AT 01965225 T AT01965225 T AT 01965225T AT E384047 T1 ATE384047 T1 AT E384047T1
Authority
AT
Austria
Prior art keywords
oxidosqualene
piperidine derivatives
cyclase inhibitors
lanosterol cyclase
lanosterol
Prior art date
Application number
AT01965225T
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Alexander Chucholowski
Henrietta Dehmlow
Olivier Morand
Sabine Wallabaum
Thomas Weller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE384047T1 publication Critical patent/ATE384047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01965225T 2000-09-08 2001-08-29 Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren ATE384047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00119677 2000-09-08

Publications (1)

Publication Number Publication Date
ATE384047T1 true ATE384047T1 (de) 2008-02-15

Family

ID=8169794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965225T ATE384047T1 (de) 2000-09-08 2001-08-29 Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren

Country Status (15)

Country Link
US (1) US6964974B2 (de)
EP (1) EP1317432B1 (de)
JP (1) JP2004508354A (de)
KR (1) KR20030027122A (de)
CN (1) CN1231466C (de)
AR (1) AR032634A1 (de)
AT (1) ATE384047T1 (de)
AU (1) AU2001285912A1 (de)
BR (1) BR0113752A (de)
CA (1) CA2419588C (de)
DE (1) DE60132468T2 (de)
ES (1) ES2298253T3 (de)
MX (1) MXPA03002034A (de)
WO (1) WO2002020483A1 (de)
ZA (1) ZA200301818B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113408A (pt) 2000-08-16 2003-06-17 Hoffmann La Roche Derivados de aminociclohexano
EP1458374A2 (de) 2001-12-14 2004-09-22 Novo Nordisk A/S Verbindungen und deren verwendung zur senkung der aktivität der hormon-abhängigen lipase
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
BRPI0519288A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
WO2012092114A2 (en) * 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
CN104039326A (zh) * 2011-10-20 2014-09-10 密苏里大学学监 用于癌症治疗的酶抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3914426A (en) * 1972-11-10 1975-10-21 Pfizer Piperidinesulfonylurea derivatives for lowering blood sugar levels
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
DE4407961A1 (de) 1994-03-10 1995-09-14 Thomae Gmbh Dr K Imidazolidin-2-one, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2190699A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19618970A1 (de) 1996-05-10 1997-11-13 Klinge Co Chem Pharm Fab Neue Thiazolopyridine
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
CA2285335A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE19806713A1 (de) 1998-02-18 1999-08-19 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ZA200301818B (en) 2004-06-21
DE60132468D1 (de) 2008-03-06
JP2004508354A (ja) 2004-03-18
CA2419588A1 (en) 2002-03-14
EP1317432A1 (de) 2003-06-11
AR032634A1 (es) 2003-11-19
US20020068753A1 (en) 2002-06-06
KR20030027122A (ko) 2003-04-03
WO2002020483A1 (en) 2002-03-14
WO2002020483A8 (en) 2002-06-06
BR0113752A (pt) 2003-07-29
MXPA03002034A (es) 2003-07-24
US6964974B2 (en) 2005-11-15
AU2001285912A1 (en) 2002-03-22
DE60132468T2 (de) 2009-01-15
ES2298253T3 (es) 2008-05-16
CN1468220A (zh) 2004-01-14
CN1231466C (zh) 2005-12-14
EP1317432B1 (de) 2008-01-16
CA2419588C (en) 2009-09-22

Similar Documents

Publication Publication Date Title
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
DK1515969T3 (da) Spiroindolinpiperidinderivater
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
NO20026125L (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
ATE447553T1 (de) Piperidinverbindungen zur verwendung als ccr-3- inhibitoren
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE268324T1 (de) 4-amino substituierte -2-subsituierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren
MA27230A1 (fr) Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE308543T1 (de) Piperidinderivate
ATE234276T1 (de) Diacylhydrazinderivate als integrin-inhibitoren
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
ATE292128T1 (de) Piperidinderivate als neurokinin 1 antagonisten
IL155986A0 (en) 4- (biphenylcarbonylamino) piperidine derivatives as mtp inhibitors
IS6413A (is) Setnir 8-arýkínólín fosfódíesterasa-4 latar
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE302781T1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
ATE553097T1 (de) Piperidin- und piperazin-substituierte n- hydroxyformamiden zur verwendung als metalloproteinaseinhibitoren
ATE384047T1 (de) Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren
ATE390413T1 (de) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridinderivaten zur verwendung als serotonin-wiederaufnahmehemmer
ATE305460T1 (de) 2-aminothiazolinderivate und ihre verwendung als no-synthase inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties